Changhua Ji, Konduru S.R. Sastry, Georg Tiefenthaler, Jennifer Cano, Tenny Tang, Zi Zong Ho, Denise Teoh, Sandhya Bohini, Antony Chen, Surya Sankuratri, Paul A. Macary, Patrick Kennedy, Han Ma, Stefan Ries, Klaus Klumpp, Erhard Kopetzki, Antonio Bertoletti – 9 June 2012 – During antiviral therapy, specific delivery of interferon‐α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration.

Wenhua Liang, Linwei Wu, Xiaoting Ling, Paul M. Schroder, Weiqiang Ju, Dongping Wang, Yushu Shang, Yuan Kong, Zhiyong Guo, Xiaoshun He – 9 June 2012 – Because of the severe organ shortage, living donor liver transplantation (LDLT) offers a timely alternative to deceased donor liver transplantation (DDLT) for patients with hepatocellular carcinoma (HCC). However, the higher recurrence rate of HCC after LDLT and the indication criteria remain controversial.

Masahiro Takahashi, Seigo Nishida, Zubin J. Panthaki, Ji Fan, Antonio Romano, Akin Tekin, Eddie R. Island, Jang I. Moon, David M. Levi, Andreas G. Tzakis – 9 June 2012

Shunji Nagai, Lloyd Brown, Atsushi Yoshida, Dean Kim, Marwan Kazimi, Marwan S. Abouljoud – 9 June 2012 – Minimally invasive procedures are considered to be safe and effective approaches to the management of surgical liver disease. However, this indication remains controversial for living donor hepatectomy. Between 2000 and 2011, living donor right hepatectomy (LDRH) was performed 58 times. Standard right hepatectomy was performed in 30 patients via a subcostal incision with a midline extension. Minimally invasive procedures began to be used for LDRH in 2008.

Giovanni Musso, Maurizio Cassader, Franco De Michieli, Floriano Rosina, Fabio Orlandi, Roberto Gambino – 8 June 2012 – Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis (SS) to nonalcoholic steatohepatitis (NASH). Though liver‐related risk seems confined to NASH, it is currently unclear whether NASH has a higher risk of cardiovascular disease (CVD) and diabetes than SS as a result of the coexistence of obesity and other cardiometabolic confounders. Adipose tissue is an emerging modulator of liver disease in NAFLD and of cardiometabolic disease in the general population.

Karolina Bojkowska, Fabio Aloisio, Marco Cassano, Adamandia Kapopoulou, Francesca Santoni de Sio, Nadine Zangger, Sandra Offner, Cristina Cartoni, Charles Thomas, Simon Quenneville, Kai Johnsson, Didier Trono – 8 June 2012 – The liver is characterized by sexually dimorphic gene expression translating into sex‐specific differences in lipid, drug, steroid hormone, and xenobiotic metabolism, with distinct responses of males and females to environmental challenges.

Zeenat Safdar, Sonja Bartolome, Norman Sussman – 4 June 2012 – Portopulmonary hypertension (POPH) is a serious complication of cirrhosis that is associated with mortality beyond that predicted by the Model for End‐Stage Liver Disease (MELD) score. Increased pulmonary vascular resistance (PVR) may be initiated by pulmonary vasoconstriction, altered levels of circulating mediators, or shear stress, and can eventually lead to the classic vascular remodeling (plexiform lesion) that characterizes POPH.

Jasmohan S. Bajaj, Leroy R. Thacker, Douglas M. Heuman, Richard K. Sterling, R. Todd Stravitz, Arun J. Sanyal, Velimir Luketic, Michael Fuchs, Ho Chong S. Gilles, James B. Wade – 4 June 2012 – Psychiatric disorders and medications may affect the cognitive performance of patients with cirrhosis and complicate the diagnosis and prediction of hepatic encephalopathy (HE).

Toru Ikegami, Ken Shirabe, Rumi Matono, Tomoharu Yoshizumi, Yuji Soejima, Hideaki Uchiyama, Hiroto Kayashima, Kazutoyo Morita, Yoshihiko Maehara – 4 June 2012 – The prevalence and clinical characteristics of bacterial pneumonia after living donor liver transplantation (LDLT) have not yet been elucidated. We performed a retrospective analysis of 346 LDLT recipients. Fifty patients (14.5%) experienced bacterial pneumonia after LDLT, and they had a higher short‐term mortality rate (42.0%) than patients with other types of bacterial infections after LDLT.

Carlo Spirli, Carola M. Morell, Luigi Locatelli, Stefano Okolicsanyi, Cecilia Ferrero, Amy K. Kim, Luca Fabris, Romina Fiorotto, Mario Strazzabosco – 31 May 2012 – Mutations in polycystins are a cause of polycystic liver disease. In polycystin‐2 (PC2)‐defective mice, cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)‐dependent activation of the Rat Sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen signal‐regulated kinase–extracellular signal‐regulated kinase (ERK) 1/2 pathway stimulates the growth of liver cysts.